CD30 Human

CD30 Human Recombinant
Shipped with Ice Packs
In Stock
Cat. No.
BT2682
Source
E.coli.
Synonyms
CD30, D1S166E, KI-1, Tumor necrosis factor receptor superfamily member 8, CD30L receptor, Ki-1 antigen, Lymphocyte activation antigen CD30, TNFRSF8.
Appearance
Sterile Filtered colorless solution.
Purity
Greater than 85% as determined by SDS-PAGE.
Usage
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Quick Inquiry

Description

Molecular Structure and Isoforms

Human CD30 is a 120 kDa type I transmembrane glycoprotein with three primary domains :

  • Extracellular domain (ECD): 361 amino acids containing six cysteine-rich repeats critical for ligand binding

  • Transmembrane domain: 28 amino acids

  • Cytracellular domain: 188 amino acids with signaling motifs

Two isoforms arise from alternative splicing:

  • Full-length membrane-bound CD30

  • A truncated cytoplasmic variant retaining only the C-terminal 132 amino acids

Comparative analysis of CD30 across species

FeatureHuman CD30Murine CD30
Extracellular length361 aa263 aa
Cysteine-rich repeats63
Sequence identity-53% (vs. human)

Data from

Biological Functions

CD30 exhibits dual roles in immune regulation:

  • Co-stimulatory signaling: Enhances antigen-induced proliferation of Th0/Th2 cells and cytokine secretion (IL-4, IL-5, IL-13)

  • Apoptosis regulation:

    • Promotes negative selection of CD4+CD8+ thymocytes

    • Limits autoreactive CD8+ T cell expansion in peripheral tissues

  • B cell modulation: Drives CXCR4/CCL5 expression and antibody production

Soluble CD30 (sCD30), generated via TACE-mediated cleavage, acts as a decoy receptor to inhibit membrane CD30 signaling .

Diagnostic Marker

CD30 is overexpressed in:

  • Hodgkin lymphoma (Reed-Sternberg cells)

  • Anaplastic large cell lymphoma (ALCL)

  • Cutaneous T cell lymphomas (mycosis fungoides)

  • 24.5% of solid tumors (e.g., testicular germ cell tumors)

CD30 variant (CD30v) expression in malignancies

Tumor TypeCD30v+ Cases (%)
B-cell NHL (high grade)62.5%
Multiple myeloma100%
Adult T-cell leukemia27.3%

Data from

Prognostic Value

  • Elevated serum sCD30 correlates with:

    • Poor survival in Hodgkin lymphoma (HR = 3.2 for levels >100 U/mL)

    • Disease activity in ALCL and autoimmune disorders

Approved Therapies

Brentuximab vedotin (anti-CD30 ADC):

  • FDA indications: Relapsed HL, systemic ALCL, CD30+ mycosis fungoides

  • Mechanism: Delivers monomethyl auristatin E to CD30+ cells

  • 5-year survival: 41% in refractory HL

Experimental Approaches

Therapy TypeMechanismClinical Outcome
Bispecific antibodiesCD30×CD3 engagement for T cell activation70% ORR in cutaneous ALCL
Naked anti-CD30 mAbsDirect tumor targetingLimited efficacy (CR rate <5%)

Data from

Research Frontiers

  • Immune modulation: CD30 activation enhances HIV replication via NF-κB in infected T cells

  • Autoimmunity: CD30 deficiency exacerbates murine autoimmune diabetes

  • Novel targets: Distinct epitopes identified for bispecific antibodies (e.g., 8D10F10 vs AC10 clone)

Product Specs

Introduction
CD30, a member of the TNF-receptor superfamily, is also known as Tumor necrosis factor receptor superfamily member 8. This receptor is found on activated, but not resting, T and B cells. CD30 interacts with TRAF2 and TRAF5, which mediate signal transduction leading to the activation of NF-kappaB. CD30 positively regulates apoptosis and has been shown to limit autoreactive CD8 effector T cell proliferation, protecting the body from autoimmunity.
Description
Recombinant human CD30 is produced in E. coli. This single, non-glycosylated polypeptide chain contains 384 amino acids (19-379a.a.), has a molecular mass of 40.8 kDa, and is purified using proprietary chromatographic techniques. It contains a 23 amino acid His-tag at the N-terminus.
Physical Appearance
Sterile, colorless, and clear solution.
Formulation
The CD30 protein solution (1mg/ml) is supplied in a buffer containing 20mM Tris-HCl (pH 8.0), 0.15M NaCl, 10% glycerol, and 1mM DTT.
Stability
For short-term storage (2-4 weeks), keep at 4°C. For long-term storage, freeze at -20°C. Adding a carrier protein (0.1% HSA or BSA) is recommended for extended storage. Avoid repeated freeze-thaw cycles.
Purity
Purity is greater than 85% as determined by SDS-PAGE analysis.
Synonyms
CD30, D1S166E, KI-1, Tumor necrosis factor receptor superfamily member 8, CD30L receptor, Ki-1 antigen, Lymphocyte activation antigen CD30, TNFRSF8.
Source
E.coli.
Amino Acid Sequence
MGSSHHHHHH SSGLVPRGSH MGSFPQDRPF EDTCHGNPSH YYDKAVRRCC YRCPMGLFPT QQCPQRPTDC RKQCEPDYYL DEADRCTACV TCSRDDLVEK TPCAWNSSRV CECRPGMFCS TSAVNSCARC FFHSVCPAGM IVKFPGTAQK NTVCEPASPG VSPACASPEN CKEPSSGTIP QAKPTPVSPA TSSASTMPVR GGTRLAQEAA SKLTRAPDSP SSVGRPSSDP GLSPTQPCPE GSGDCRKQCE PDYYLDEAGR CTACVSCSRD DLVEKTPCAW NSSRTCECRP GMICATSATN SCARCVPYPI CAAETVTKPQ DMAEKDTTFE APPLGTQPDC NPTPENGEAP ASTSPTQSLL VDSQASKTLP IPTSAPVALS STGK.

Product Science Overview

Structure and Function

Mature human CD30 consists of:

  • A 361 amino acid (aa) extracellular domain (ECD) with six cysteine-rich repeats
  • A 28 aa transmembrane segment
  • A 188 aa cytoplasmic domain

CD30 plays a crucial role in the regulation of immune responses. It is involved in the activation and proliferation of T cells and B cells, and it can influence the survival and apoptosis of these cells. The interaction of CD30 with its ligand, CD30L (CD30 Ligand/TNFSF8), can lead to the activation of various signaling pathways that are important for immune regulation .

Recombinant CD30

Recombinant human CD30 is produced using recombinant DNA technology, which involves inserting the gene encoding CD30 into a suitable expression system, such as a mouse myeloma cell line (NS0-derived human CD30/TNFRSF8 protein) . This allows for the production of large quantities of CD30 protein for research and therapeutic purposes.

Recombinant CD30 is used in various applications, including:

  • Research: Studying the role of CD30 in immune responses and its involvement in diseases such as Hodgkin’s lymphoma and other lymphomas.
  • Therapeutics: Developing targeted therapies for diseases associated with CD30 expression, such as antibody-drug conjugates (ADCs) that specifically target CD30-expressing cells.
Applications and Importance

The study of CD30 and its interactions with CD30L has significant implications for understanding and treating various immune-related diseases. By targeting CD30, researchers and clinicians can develop more effective therapies for conditions such as Hodgkin’s lymphoma, non-Hodgkin’s lymphomas, and other diseases involving abnormal T and B cell activation.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Category

Service

THE BIOTEK
THE BioTek is a global biotech company offering highly purified proteins for research in cancer, apoptosis, development, endocrinology, immunology, neuroscience, proteases, and stem cells.
  • Contact
  • Address: 1925 E Maple Ave, El Segundo, CA 90245 United States
  • Phone : +1 201-285-7826
  • Email : info@thebiotek.com
  • Hours : Mon.-Fri. 9:00 AM - 5:00 PM
© Copyright 2024 Thebiotek. All Rights Reserved.